These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26921595)

  • 21. Reduced visual function associated with infantile spasms in children on vigabatrin therapy.
    Hammoudi DS; Lee SS; Madison A; Mirabella G; Buncic JR; Logan WJ; Snead OC; Westall CA
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):514-20. PubMed ID: 15671276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vigabatrin therapy in infantile spasms.
    Kankirawatana P; Raksadawan N; Balangkura K
    J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S778-83. PubMed ID: 12403260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
    Durbin S; Mirabella G; Buncic JR; Westall CA
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):4011-6. PubMed ID: 19279311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms.
    Frost JD; Le JT; Lee CL; Ballester-Rosado C; Hrachovy RA; Swann JW
    Neurobiol Dis; 2015 Oct; 82():1-11. PubMed ID: 26026423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis.
    Biswas A; Yossofzai O; Vincent A; Go C; Widjaja E
    Expert Rev Neurother; 2020 Dec; 20(12):1315-1324. PubMed ID: 33078964
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual field constriction in 91 Finnish children treated with vigabatrin.
    Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
    Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fifteen years of real-world data on the use of vigabatrin in individuals with infantile epileptic spasms syndrome.
    Kuchenbuch M; Lo Barco T; Chemaly N; Chiron C; Nabbout R
    Epilepsia; 2024 Feb; 65(2):430-444. PubMed ID: 37872396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vigabatrin and visual field defects in pediatric epilepsy patients.
    You SJ; Ahn H; Ko TS
    J Korean Med Sci; 2006 Aug; 21(4):728-32. PubMed ID: 16891821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vigabatrin for infantile spasms.
    Pesaturo KA; Spooner LM; Belliveau P
    Pharmacotherapy; 2011 Mar; 31(3):298-311. PubMed ID: 21361740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.
    Vigevano F; Cilio MR
    Epilepsia; 1997 Dec; 38(12):1270-4. PubMed ID: 9578521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?
    Desnous B; Lenoir M; Bitton JY; Arbour M; Villeneuve N; Whiting S; Mohammed I; Wirrell EC; Bello-Espinosa L; Ronen GM; Lortie A; Birca A
    Seizure; 2021 Oct; 91():503-506. PubMed ID: 34371246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.
    Ibrahim S; Gulab S; Ishaque S; Saleem T
    BMC Pediatr; 2010 Jan; 10():1. PubMed ID: 20078871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and tolerability of vigabatrin in West syndrome].
    Moraes MH; Montenegro MA; Franzon RC; Avila JO; Guerreiro MM
    Arq Neuropsiquiatr; 2005 Jun; 63(2B):469-73. PubMed ID: 16059600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vigabatrin in the treatment of infantile spasms.
    Koo B
    Pediatr Neurol; 1999 Feb; 20(2):106-10. PubMed ID: 10082337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
    Krauss G; Faught E; Foroozan R; Pellock JM; Sergott RC; Shields WD; Ziemann A; Dribinsky Y; Lee D; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Mar; 56():15-9. PubMed ID: 26807550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute encephalopathy associated with vigabatrin in a six-month-old girl.
    Haas-Lude K; Wolff M; Riethmüller J; Niemann G; Krägeloh-Mann I
    Epilepsia; 2000 May; 41(5):628-30. PubMed ID: 10802771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
    Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
    Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.